A clinical implication from this finding is that genetic susceptibility may override modifiable environmental factors in patients diagnosed with NAFLD and patients with risk alleles in PNPLA3 may benefit from additional intensive surveillance to prevent hepatic fibrosis progression. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.